Please use this identifier to cite or link to this item:
|Title:||A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis.|
|Authors:||Levidiotis, Vicki;Freeman, Craig;Punler, Malcolm;Martinello, Paul;Creese, Brian;Ferro, Vito;van der Vlag, Johan;Berden, Jo H M;Parish, Christopher R;Power, David Anthony|
|Affiliation:||Austin Research Institute, Department of Nephrology, University of Melbourne, Australia. Vicki.Levidiotis@austin.org.au <Vicki.Levidiotis@austin.org.au>|
|Citation:||Journal of the American Society of Nephrology : Jasn; 15(11): 2882-92|
|Abstract:||The beta-D-endoglycosidase heparanase has been proposed to be important in the pathogenesis of proteinuria by acting to selectively degrade the negatively charged side chains of heparan sulfate proteoglycans (HSPG) within the glomerular basement membrane (GBM). A loss of the negatively charged HSPG may result in alteration of the permselective properties of the GBM, loss of glomerular epithelial and endothelial cell anchor points, and liberation of growth factors. This study examined the effect of PI-88, a sulfated oligosaccharide heparanase inhibitor, on renal function, glomerular ultrastructure, and proteinuria. Continuous PI-88 infusion at 25 mg/kg per d did not adversely affect animal behavior, growth, or GFR. Cortical tubular vacuolation, however, was observed by light microscopy, and GBM thickness was significantly reduced in these animals (P < 0.0002). Tissue distribution studies using [(35)S]-labeled PI-88 revealed high levels of radioactivity in the kidney after a single subcutaneous injection of 25 mg/kg, suggesting protracted accumulation; moreover, active PI-88 was detected in urine. In passive Heymann nephritis, PI-88 delivered as a continuous infusion at 25 mg/kg per d significantly reduced autologous-phase proteinuria, at day 14 (P < 0.009), in the absence of altered sheep antibody deposition, C5b-9 deposition, and circulating rat anti-sheep antibody titers. Glomerular vascular endothelial growth factor and fibroblast growth factor expression was unaffected by PI-88 administration. However, PI-88 administration significantly prevented glomerular HSPG loss as demonstrated by quantitative immunofluorescence studies (P < 0.0001) in the absence of altered agrin distribution. These data therefore confirm the importance of heparanase in the development of proteinuria.|
|Internal ID Number:||15504941|
Complement Membrane Attack Complex.metabolism
Fluorescent Antibody Technique
Heparan Sulfate Proteoglycans.metabolism
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.